SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss the potential impact of a reported earnings miss, attributed to a tax dispute in Brazil, despite revenue being in line with expectations. Community members are debating whether this dip presents a buying opportunity or signals a larger correction for the streaming giant, with some questioning the company's valuation and future growth prospects in an increasingly competitive market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is seeing active discussion despite a widespread AWS outage that impacted numerous online services.  The community is weighing the long-term implications of the outage against the potential for a buying opportunity, especially with earnings approaching. Bullish sentiment remains, with some seeing it as a demonstration of AWS's dominance and integral role in the internet infrastructure.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a sector-wide selloff, sparking debates about potential manipulation and overbought conditions; the community is weighing whether this dip presents a buying opportunity, or signals further declines. Discussions also involve upcoming earnings and speculation around potential deals, particularly concerning AI data centers. Some traders are expressing concerns about dilution and the stock's correlation with Bitcoin's volatility.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as traders debate recent price volatility and potential market manipulation, with some pointing to ETF activity and large players impacting price action. Community members are discussing potential bull traps and the impact of news events, while others speculate on future price movements and compare Bitcoin's performance to gold. Sentiment is mixed, with both bullish and bearish viewpoints being shared amid discussions about market cycles and potential catalysts.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending amid discussions about its pullback from recent highs, with community members debating whether it presents a buying opportunity or signals a deeper correction. Some traders are pointing to potential manipulation and profit-taking, while others remain bullish on the company's long-term prospects in the AI and data center space. The conversation also includes mentions of sector peers and the broader market's influence.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as the price of gold experiences significant volatility, with some investors viewing recent drops as bear traps and opportunities to buy, while others point to overbought conditions and potential pullbacks. Community discussions revolve around factors like central bank activity, global economic uncertainty, and the impact of potential shifts in currency dominance. Some traders are also noting technical indicators and hedging strategies amid the fluctuating prices.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors discuss its AI strategy and potential partnerships, including rumored collaborations with Anthropic. Community talking points highlight Google's AI capabilities, such as Gemini, DeepMind, and GCP, emphasizing the company's potential to dominate the AI landscape. Broader discussions cover capital expenditures on data centers and a generally positive outlook on the stock's valuation relative to peers.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending due to positive earnings reports, with impressive growth in da Vinci procedures and system placements driving optimism. The community is discussing the potential for the stock to reach new highs, with some highlighting the company's strong market position and recurring revenue model. Despite concerns about margins and tariffs, the overall sentiment is bullish, driven by the increasing adoption of robotic surgery.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is under pressure as cautious guidance and tariff concerns overshadow otherwise solid analog-chip growth, sparking community debate about a potential long-term slowdown. The community is actively discussing whether recent price action signals a temporary dip or reflects deeper fundamental weakness for the semiconductor company. Investor sentiment seems to be down due to the unclear guidance.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending downwards, sparking community debate about potential bottom levels and optimal entry points. Investors are weighing the impact of recent AI sector-wide pullbacks against the company's long-term potential, particularly its Microsoft deal and other strategic partnerships. Community members are closely monitoring for an earnings date announcement, anticipating it could be a catalyst for a reversal.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Equity

Immuneering Stock Rises 21.7% on Supply Agreement With LLY

IMRX jumps 21.7% after striking a supply deal with Eli Lilly to test atebimetinib with the latter's olomorasib in non-small cell lung cancer.

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the latter’s investigational cancer drug Olomorasib.Immuneering <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/25/3138395/0/en/Immuneering-Announces-Clinical-Supply-Agreement-with-Lilly-to-Evaluate-Atebimetinib-in-Combination-with-Olomorasib.html">said</a> that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer (NSCLC) who have progressed on prior therapy.In February, Immuneering announced a similar clinical trial agreement with Regeneron Pharmaceuticals to evaluate Atebimetinib in combination with Libtayo in patients with advanced non-small cell lung cancer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> trended within ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. IMRX stock traded 15% higher at the time of writing.<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_25_at_12_21_56_PM_png_6149d7e374.webp" alt="IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>IMRX's Sentiment Meter and Message Volume as of 12:25 p.m. ET on Aug. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they will buy more on dips.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/626436428</stembedurl>Another user praised the company saying it has excellent products and good management.<stembedurl>https://stocktwits.com/OptimistJP/message/626406127</stembedurl>Chief Medical Officer of Immuneering Igor Matushansky said that the combination of the company’s drug with Lilly’s has the potential for enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy.&nbsp;&nbsp;&nbsp;&nbsp;“This dual-targeted approach has the potential to improve outcomes in a population with limited effective treatment options,” Matushansky added. Immuneering further said that it will maintain global development and commercialization rights to its drug Atebimetinib.IMRX stock is up by 156% this year and by about 381% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-exec-hints-at-possible-price-hike-on-model-y-in-us/chsssVVRdSR">Tesla Executive Hints At Possible Price Hike On Model Y In US: Retail Highlights Negative Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell lung cancer who have progressed on prior therapy.

Shares&nbsp;of Immuneering Corp saw increased retail chatter on Tuesday after the company reported positive interim results from its Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.The stock&nbsp;initially surged on the news during morning trade&nbsp;but closed down 23.2% at $1.82 on Tuesday and slipped another 2.2% to $1.78 in after-hours trading.Trading activity likely indicated profit-taking, as Immuneering’s stock has gained more than 25% over the past month.The data demonstrated an overall survival (OS) rate of 94% and a progression-free survival (PFS) rate of 72% at 6 months among 34 patients who received atebimetinib at 320 mg once daily plus modified mGnP.&nbsp;Median OS and PFS had not yet been reached.&nbsp;The benchmark 6-month OS and PFS rates for&nbsp;the current standard-of-care treatment in this population are 67% and 44%, respectively.The overall response rate stood at 39%, with disease control seen in 81% of patients.&nbsp;Investigators noted durable tumor regressions, with multiple lesions reportedly rendered undetectable.&nbsp;No Grade 3 or higher adverse events were observed across most categories typically linked to standard chemotherapy regimens.The data prompted Immuneering to increase the trial’s target enrollment to 50 patients.&nbsp;A pivotal, randomized trial is planned for 2026, pending regulatory feedback later this year.Immuneering said additional Phase 2a data and regulatory milestones are expected in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user noted that the stock has never undergone a reverse split and suggested it has multiple upside targets, even speculating on potential buyout interest.&nbsp;<stembedurl>https://stocktwits.com/sam92/message/618211510</stembedurl>Another long-time holder said belief in the stock remains strong.<stembedurl>https://stocktwits.com/Starkravingmad/message/618210680</stembedurl>The stock has declined 17.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally

The company plans to launch a pivotal trial in 2026 and expects additional clinical data and regulatory feedback by the end of 2025. 

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options PR Newswire VANCOUVER, BC, Dec. 23, 2024 Issued on...

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response...

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment

Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment PR Newswire...

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...

Immuneering price target lowered by $12 at Mizuho, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.85
Prev Close	$5.61
Open	$5.55
Dividend Yield	0.00%
50-Day Moving Average	$6.23
Beta	1.21
Avg. Volume	2.92M
PE Ratio	-3.09

52-Week High	$10.08
52-Week Low	$1.10
Market Capitalization	$354.1M
EPS (Annual)	-$2.04
Price to Book	7.28
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMRX News

IMRXImmuneering Corp